CY-5, a novel GLP-1/GIP dual receptor agonist, was recently discovered by Liu et al., which showed efficacy in reducing serum lipids, LFTs, and biopsy-proven hepatic steatosis in an AMLN diet NAFLD mouse model [47]. The gene discussed is GCG; the disease is fatty liver disease.